Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 5/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13379895 | 0.83 | ALDH1A1 (0.44) | QDPRSIGMAR1GAAMEN1KMT2A | |
| SCHEMBL18372250 | 0.80 | NAMPT (0.33) | — | |
| SCHEMBL10201924 | 0.77 | DRD4 (0.39) | QDPRGAAKDM4E | |
| SCHEMBL14587400 | 0.75 | DRD2 (0.41) | QDPRKDM4EMEN1THRBKMT2A | |
| SCHEMBL13406301 | 0.75 | DRD2 (0.41) | THRB | |
| SCHEMBL16546209 | 0.75 | QDPR (0.33) | QDPR | |
| SCHEMBL578138 | 0.74 | QDPR (0.68) | QDPRSIGMAR1SLC6A4 | |
| SCHEMBL27159736 | 0.73 | KDM4E (0.48) | QDPRSIGMAR1HTR2CSLC6A4KDM4E | |
| SCHEMBL10201925 | 0.72 | MAPT (0.39) | QDPR | |
| SCHEMBL4947674 | 0.69 | ALDH1A1 (0.50) | QDPRSIGMAR1MMP2MMP3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643967-B2 | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20170008885-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008885-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TLR9, TLR7, TLR1 | QDPR 1451/4885SIGMAR1 3994/4885HTR2C 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.